ARTICLE | Product Development
Part 2 of an interview with AstraZeneca’s head of oncology
By C. Simone Fishburn, Editor in Chief
July 20, 2024 12:28 AM UTC
If Susan Galbraith is right, within a decade backbone chemotherapy may have been largely displaced, many more patients will receive curative radiotherapy, and long-term survival benefits in cancer may be radically improved by bringing new treatments into earlier-line therapy and using better screening tools, including some powered by AI.
Galbraith, EVP of oncology R&D at AstraZeneca plc (LSE:AZN; NASDAQ:AZN), sat down with BioCentury to discuss the past and the future of cancer research, and AstraZeneca’s approach. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652978/susan-galbraith-five-trends-will-drive-the-future-of-cancer-treatment